Susan T. Johnson

It's time to phase in<i><scp>RHD</scp></i>genotyping for patients with a serologic weak<scp>D</scp>phenotype

S. Gerald Sandler, Willy A. Flegel, Connie M. Westhoff et al. · Transfusion · 2014 · 194 citations · Full text

Immunohematology, Rhd Genotyping, Genetics +20

One center's experience: the serology and drugs associated with drug‐induced immune hemolytic anemia—a new paradigm

Susan T. Johnson, Judith T. Fueger, Jerome L. Gottschall · Transfusion · 2007 · 119 citations

Sensitivity to a Metabolite of Diclofenac as a Cause of Acute Immune Hemolytic Anemia

Daniel W. Bougie, Susan T. Johnson, Lee Ann Weitekamp et al. · Blood · 1997 · 77 citations

High‐throughput red blood cell antigen genotyping using a nanofluidic real‐time polymerase chain reaction platform

Kathleen A. Hopp, Kathleen M. Weber, Daniel B. Bellissimo et al. · Transfusion · 2009 · 66 citations

It's time to phase out “serologic weak D phenotype” and resolve D types with <i>RHD</i> genotyping including weak D type 4

Willy A. Flegel, Gregory A. Denomme, John T. Queenan et al. · Transfusion · 2020 · 52 citations · Full text

D Types, Financial Support, Genetics +6